Percutaneous tricuspid valve repair: A safer alternative to traditional approaches?

Key Points The use of the PASCAL transcatheter valve repair system is a safe and feasible approach for treating patients with severe, symptomatic tricuspid regurgitation and is associated with improved quality‐of‐life outcomes at 30 days. The TriCLASP study adds to the growing body of evidence suppo...

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 100; no. 7; pp. 1300 - 1301
Main Authors El Hajj, Milad, Krajcer, Zvonimir
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.12.2022
Subjects
Cardiac Catheterization - adverse effects
Heart Valve Prosthesis Implantation - adverse effects
Humans
PASCAL
transcatheter tricuspid valve repair
Treatment Outcome
tricuspid regurgitation
Tricuspid valve
Tricuspid Valve - diagnostic imaging
Tricuspid Valve - surgery
Tricuspid Valve Insufficiency - diagnostic imaging
Tricuspid Valve Insufficiency - surgery
tricuspid regurgitation
PASCAL
transcatheter tricuspid valve repair
Online AccessGet full text

Cover

More Information
Summary:Key Points The use of the PASCAL transcatheter valve repair system is a safe and feasible approach for treating patients with severe, symptomatic tricuspid regurgitation and is associated with improved quality‐of‐life outcomes at 30 days. The TriCLASP study adds to the growing body of evidence supporting the use of transcatheter tricuspid valve interventions for treating severe tricuspid regurgitation in high‐risk surgical patients. In the highly anticipated CLASP II TR pivotal trial (NCT04097145), patients will be randomized to receive treatment with the PASCAL system and optimal medical therapy or optimal medical therapy alone.
Bibliography:Expert Article Analysis for
Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30‐day results
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.30497